Denileukin Diftitox

  (DEH-nih-LOO-kin DIF-tih-tox)

This page contains brief information about denileukin diftitox and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		ONTAK
FDA Approved:		Yes

FDA Approval for Denileukin Diftitox

Denileukin diftitox is approved to treat:

• Cutaneous T-cell lymphoma (a certain type). It is used in patients whose disease has not gotten better with other treatment or has recurred (come back).

Denileukin diftitox is also being studied in the treatment of other types of cancer.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Denileukin Diftitox - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Clinical Trial Results: Drug Slows Progression of Cutaneous T-Cell Lymphoma - Important clinical trial results for this drug, background information, and how the trial was done.

Find Clinical Trials for Denileukin Diftitox - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top